- Home
- NZF vs HAE Comparison
NZF vs HAE Comparison
Compare NZF & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NZF
- HAE
- Stock Information
- Founded
- NZF 2001
- HAE 1971
- Country
- NZF United States
- HAE United States
- Employees
- NZF N/A
- HAE N/A
- Industry
- NZF Finance Companies
- HAE Medical/Dental Instruments
- Sector
- NZF Finance
- HAE Health Care
- Exchange
- NZF Nasdaq
- HAE Nasdaq
- Market Cap
- NZF 2.4B
- HAE 2.5B
- IPO Year
- NZF N/A
- HAE 1991
- Fundamental
- Price
- NZF $12.74
- HAE $73.71
- Analyst Decision
- NZF
- HAE Strong Buy
- Analyst Count
- NZF 0
- HAE 9
- Target Price
- NZF N/A
- HAE $79.67
- AVG Volume (30 Days)
- NZF 496.8K
- HAE 949.3K
- Earning Date
- NZF 01-01-0001
- HAE 11-06-2025
- Dividend Yield
- NZF 4.67%
- HAE N/A
- EPS Growth
- NZF N/A
- HAE 42.54
- EPS
- NZF N/A
- HAE 3.44
- Revenue
- NZF N/A
- HAE $1,327,850,000.00
- Revenue This Year
- NZF N/A
- HAE N/A
- Revenue Next Year
- NZF N/A
- HAE $6.35
- P/E Ratio
- NZF N/A
- HAE $20.88
- Revenue Growth
- NZF N/A
- HAE N/A
- 52 Week Low
- NZF $9.82
- HAE $47.32
- 52 Week High
- NZF $12.29
- HAE $94.99
- Technical
- Relative Strength Index (RSI)
- NZF 62.19
- HAE 88.22
- Support Level
- NZF $12.53
- HAE $49.96
- Resistance Level
- NZF $12.55
- HAE $71.37
- Average True Range (ATR)
- NZF 0.10
- HAE 2.38
- MACD
- NZF 0.02
- HAE 2.71
- Stochastic Oscillator
- NZF 79.12
- HAE 98.33
About NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.